trial was not powered or designed to assess cardiovascular event outcome. it was to prove biologic effect in vivo on cholesterol and safety.
the point of the phase 3 is to assess cv outcomes which need longer term followup and bigger sample size.
this is very good news but i guess the average investor may not realise this and think that it was supposed to show lower cardiovascular events, which is not true.
oh well, their loss
- Forums
- ASX - By Stock
- CSL
- Ann: Positive Results from CSL112 Phase 2b Trial
Ann: Positive Results from CSL112 Phase 2b Trial, page-6
-
-
- There are more pages in this discussion • 42 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CSL (ASX) to my watchlist
(20min delay)
|
|||||
Last
$300.26 |
Change
-1.400(0.46%) |
Mkt cap ! $145.3B |
Open | High | Low | Value | Volume |
$303.31 | $303.47 | $299.56 | $148.6M | 498.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 276 | $300.19 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$300.34 | 1250 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 250 | 300.000 |
1 | 99 | 299.950 |
1 | 5 | 299.650 |
1 | 6 | 299.500 |
2 | 32 | 299.100 |
Price($) | Vol. | No. |
---|---|---|
300.650 | 59 | 1 |
301.160 | 55 | 1 |
301.660 | 35 | 1 |
301.890 | 19 | 1 |
302.000 | 53 | 2 |
Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
Featured News
CSL (ASX) Chart |
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online